Abstract
Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Current Drug Targets
Title: Prophylactic Neuroprotection
Volume: 8 Issue: 7
Author(s): Sean I. Savitz and Marc Fisher
Affiliation:
Keywords: Neuroprotection, prophylactic, statins, infarct, stroke
Abstract: Ischemic brain injury can be anticipated in a number of clinical settings such as procedures associated with a high-risk for stroke, patients with transient ischemic attacks or minor strokes who are at substantial risk for early recurrence and patients with multiple vascular risk factors with an enhanced risk for ischemic stroke over many years. In such high-risk settings, it may be possible to employ neuroprotective drugs prophylactically to reduce the extent and clinical consequences of ischemic events. The concept of prophylactic neuroprotection can be envisioned for varying time periods and with a variety of drug classes depending upon the target population. This review will focus on which target populations should be considered for prophylactic neuroprotection trials and which drugs might be used in such trials.
Export Options
About this article
Cite this article as:
Sean I. Savitz and Marc Fisher , Prophylactic Neuroprotection, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077382
DOI https://dx.doi.org/10.2174/138945007781077382 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
Recent Patents on Anti-Infective Drug Discovery Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease
Current Alzheimer Research Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157
Current Medicinal Chemistry Modulation of the Peripheral and Central Inflammatory Responses by a-Melanocyte Stimulating Hormone
Current Protein & Peptide Science Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Commentary (Research Highlights: Linking Productive Autophagy to Neuroprotection: Potential Implications for Anti-Ischemic Therapy)
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Patent Selections:
Recent Patents on Biotechnology Overview of Angiogenesis and the use of Bevacizumab in Patients with Malignant Gliomas
Current Signal Transduction Therapy Extracellular Vesicles Isolated from Mesenchymal Stromal Cells Primed with Hypoxia: Novel Strategy in Regenerative Medicine
Current Stem Cell Research & Therapy Preface [Hot Topic: New Clinical Applications for Naturally Occurring Peptide Toxins (Guest Editors: Robert Jones / Graeme Semple)]
Current Medicinal Chemistry Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Cell-based Therapy for Ocular Disorders: A Promising Frontier
Current Stem Cell Research & Therapy Microglia-Targeted Pharmacotherapy in Retinal Neurodegenerative Diseases
Current Drug Targets Effect of Edaravone on MicroRNA Expression in Exosomes after Hepatic Ischemia-reperfusion Injury
Current Molecular Pharmacology